Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Zender

Showing results (71-80 of 192) with videos related to

Pageof 20
Sort By:
Journal of Medicinal Chemistry|May 22, 2025
A "Ligand First" Approach toward Selective, Covalent JNK2/3 InhibitorsValentin R Wydra, Nicole Plank, Stefan Zwirner, et al.
World Journal of Gastroenterology|March 9, 2005
Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liverTimm Kirchhoff, Lars Zender, Sonja Merkesdal, et al.
Nature Cell Biology|August 1, 2017
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescenceSelene Glück, Baptiste Guey, Muhammet Fatih Gulen, et al.
European Journal of Medicinal Chemistry|March 24, 2022
Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivityTeodor Dimitrov, Cetin Anli, Athina Anastasia Moschopoulou, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 31, 2009
Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologuesFlorian Kühnel, Engin Gürlevik, Thomas C Wirth, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 4, 2026
Targeting of p53-Transcriptional Dysfunction by Conditionally Replicating Adenovirus Is Not Limited by p53-HomologuesFlorian Kühnel, Engin Gürlevik, Thomas C Wirth, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2024
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in <i>KRAS</i>-mutant cancersRobin A Jansen, Sara Mainardi, Matheus Henrique Dias, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Primary Renal Neuroendocrine Tumor: Diagnostic Challenges in a Rare Entity-A Case ReportRaphaela D Lewetag, Katharina Kluthe, Nils F Trautwein, et al.
Frontiers in Endocrinology|January 23, 2024
Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3Martina Hinterleitner, Ruben Pfeiffer, Nils F Trautwein, et al.
Frontiers in Oncology|April 5, 2021
Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer ProgressionClemens Hinterleitner, Yanjun Zhou, Claudia Tandler, et al.
Pageof 20

Showing results (71-80 of 192) with videos related to

Sort By:
Pageof 20
Journal of Medicinal Chemistry|May 22, 2025
A "Ligand First" Approach toward Selective, Covalent JNK2/3 InhibitorsValentin R Wydra, Nicole Plank, Stefan Zwirner, et al.
World Journal of Gastroenterology|March 9, 2005
Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liverTimm Kirchhoff, Lars Zender, Sonja Merkesdal, et al.
Nature Cell Biology|August 1, 2017
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescenceSelene Glück, Baptiste Guey, Muhammet Fatih Gulen, et al.
European Journal of Medicinal Chemistry|March 24, 2022
Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivityTeodor Dimitrov, Cetin Anli, Athina Anastasia Moschopoulou, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 31, 2009
Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologuesFlorian Kühnel, Engin Gürlevik, Thomas C Wirth, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 4, 2026
Targeting of p53-Transcriptional Dysfunction by Conditionally Replicating Adenovirus Is Not Limited by p53-HomologuesFlorian Kühnel, Engin Gürlevik, Thomas C Wirth, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2024
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in <i>KRAS</i>-mutant cancersRobin A Jansen, Sara Mainardi, Matheus Henrique Dias, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Primary Renal Neuroendocrine Tumor: Diagnostic Challenges in a Rare Entity-A Case ReportRaphaela D Lewetag, Katharina Kluthe, Nils F Trautwein, et al.
Frontiers in Endocrinology|January 23, 2024
Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3Martina Hinterleitner, Ruben Pfeiffer, Nils F Trautwein, et al.
Frontiers in Oncology|April 5, 2021
Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer ProgressionClemens Hinterleitner, Yanjun Zhou, Claudia Tandler, et al.
Pageof 20